STOCK TITAN

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Lexicon Pharmaceuticals reported Q3 2024 financial results with net sales of $1.7 million for INPEFA. The company announced an exclusive licensing agreement with Viatris for sotagliflozin outside U.S. and Europe, receiving a $25 million upfront payment with potential for $197 million in additional milestones. Net loss was $64.8 million ($0.18/share). R&D expenses increased to $25.8 million, while SG&A expenses rose to $39.6 million. Cash position stood at $258.4 million. The company completed enrollment screening for Phase 2b PROGRESS study of LX9211, with topline data expected in Q1 2025.

Lexicon Pharmaceuticals ha riportato i risultati finanziari del terzo trimestre 2024, con vendite nette di 1,7 milioni di dollari per INPEFA. L'azienda ha annunciato un accordo di licenza esclusivo con Viatris per sotagliflozin al di fuori degli Stati Uniti e dell'Europa, ricevendo un pagamento iniziale di 25 milioni di dollari con la possibilità di ulteriori 197 milioni di dollari in traguardi addizionali. La perdita netta è stata di 64,8 milioni di dollari (0,18 dollari per azione). Le spese per R&S sono aumentate a 25,8 milioni di dollari, mentre le spese SG&A sono salite a 39,6 milioni di dollari. La posizione di cassa era di 258,4 milioni di dollari. L'azienda ha completato lo screening per l'arruolamento dello studio di Fase 2b PROGRESS di LX9211, con i dati preliminari attesi nel primo trimestre del 2025.

Lexicon Pharmaceuticals reportó los resultados financieros del tercer trimestre de 2024, con ventas netas de 1.7 millones de dólares para INPEFA. La compañía anunció un acuerdo de licencia exclusivo con Viatris para el sotagliflozina fuera de EE. UU. y Europa, recibiendo un pago inicial de 25 millones de dólares con el potencial de 197 millones de dólares en hitos adicionales. La pérdida neta fue de 64.8 millones de dólares (0.18 dólares por acción). Los gastos de I+D aumentaron a 25.8 millones de dólares, mientras que los gastos SG&A aumentaron a 39.6 millones de dólares. La posición de efectivo se situó en 258.4 millones de dólares. La compañía completó el reclutamiento para el estudio de Fase 2b PROGRESS de LX9211, con datos preliminares esperados para el primer trimestre de 2025.

렉시콘 제약은 2024년 3분기 재무 결과를 보고했으며, INPEFA의 순매출이 170만 달러에 달했습니다. 회사는 미국과 유럽 외에서 소타글리플로신에 대해 비아트리스와 독점 라이센스 계약을 체결하고, 2500만 달러의 선불금을 받았으며 추가적인 마일스톤으로 1억 9700만 달러의 가능성을 가지고 있습니다. 순손실은 6480만 달러 (주당 0.18 달러)였습니다. 연구개발 비용은 2580만 달러로 증가했으며, SG&A 비용은 3960만 달러로 상승했습니다. 현금 보유량은 2억 5840만 달러에 달합니다. 회사는 LX9211의 2b 단계 PROGRESS 연구에 대한 등록 스크리닝을 완료했으며, 주요 데이터는 2025년 1분기에 예상됩니다.

Lexicon Pharmaceuticals a annoncé ses résultats financiers pour le troisième trimestre de 2024, avec des ventes nettes de 1,7 million de dollars pour INPEFA. L'entreprise a annoncé un accord de licence exclusif avec Viatris pour le sotagliflozin en dehors des États-Unis et de l'Europe, recevant un paiement initial de 25 millions de dollars avec un potentiel de 197 millions de dollars en jalons supplémentaires. La perte nette a été de 64,8 millions de dollars (0,18 dollar par action). Les dépenses en R&D ont augmenté à 25,8 millions de dollars, tandis que les dépenses SG&A ont grimpé à 39,6 millions de dollars. La position de trésorerie s'élevait à 258,4 millions de dollars. L'entreprise a terminé le dépistage d'inscription pour l'étude de Phase 2b PROGRESS de LX9211, avec des données préliminaires attendues au premier trimestre 2025.

Lexicon Pharmaceuticals hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit Nettoumsätzen von 1,7 Millionen USD für INPEFA. Das Unternehmen gab eine exklusive Lizenzvereinbarung mit Viatris für Sotagliflozin außerhalb der USA und Europa bekannt und erhielt eine Vorauszahlung von 25 Millionen USD mit dem Potenzial für 197 Millionen USD an zusätzlichen Meilensteinen. Der Nettoverlust betrug 64,8 Millionen USD (0,18 USD pro Aktie). Die F&E-Ausgaben stiegen auf 25,8 Millionen USD, während die SG&A-Ausgaben auf 39,6 Millionen USD anstiegen. Die Liquiditätsposition betrug 258,4 Millionen USD. Das Unternehmen hat das Screening für die Rekrutierung der Phase 2b PROGRESS-Studie von LX9211 abgeschlossen, wobei die ersten Daten im ersten Quartal 2025 erwartet werden.

Positive
  • Secured $25 million upfront payment from Viatris licensing deal with potential for $197 million additional milestones
  • Strong cash position of $258.4 million, up from $170.0 million in December 2023
  • 18% increase in active INPEFA prescribers
Negative
  • Net loss increased to $64.8 million from $50.5 million year-over-year
  • R&D expenses increased 46.6% to $25.8 million
  • SG&A expenses rose 23% to $39.6 million
  • FDA Advisory Committee voted 11-3 against ZYNQUISTA approval for T1D with CKD
  • 50% reduction in field force due to strategic repositioning

Insights

The Q3 results reveal significant financial developments with mixed implications. Net sales of INPEFA at $1.7 million show early market penetration, while the $25 million upfront payment from Viatris plus potential $197 million in milestones creates meaningful revenue opportunities. However, increased R&D expenses to $25.8 million and SG&A costs of $39.6 million led to a wider net loss of $64.8 million. The cash position remains strong at $258.4 million, providing runway for key clinical programs.

The 50% reduction in field force signals a strategic pivot to optimize commercial spend, though severance costs impacted Q3 expenses. The Viatris deal demonstrates business development capabilities while expanding global market reach.

The pipeline progress shows mixed signals for investors. The FDA Advisory Committee's 11-3 vote against ZYNQUISTA for T1D with CKD creates uncertainty ahead of the December 20 PDUFA date, though alternative T1D subpopulations may still present opportunities. The completion of enrollment screening for LX9211's Phase 2b DPNP study ahead of schedule is positive, with data expected Q1 2025. This non-opioid therapy could address a significant unmet need.

The advancement of SONATA HCM Phase 3 trial and LX9851 for obesity represent additional value drivers, diversifying beyond INPEFA. The 18% growth in active prescribers for INPEFA demonstrates early physician adoption despite commercial challenges.

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe

Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024

Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP); Topline Data Expected in Q1 2025

Executed Repositioning of INPEFA® (sotagliflozin); Net Sales of $1.7 Million in Q3 2024

Conference Call and Webcast at 5:00pm ET

THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2024 and provided an update on key corporate milestones.

“The past few months have been transformational for Lexicon. In addition to reaching significant milestones for several of our novel investigational medicines, we also entered into a new exclusive licensing agreement to expand the reach of sotagliflozin outside of the U.S. and Europe and strategically realigned our resources to support the wealth of opportunities in our pipeline,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “With an updated executive leadership team and strong clinical development, medical, and commercial capabilities concentrated in cardiometabolic disease, we are well positioned to embark on the next phase of our Lead to Succeed strategy. We look forward to continuing this momentum with the upcoming PDUFA target action date for ZYNQUISTA on December 20, 2024, and topline results of our Phase 2b clinical trial for LX9211 anticipated in the first quarter of next year.”

Third Quarter 2024 Pipeline Highlights

Exclusive Licensing Agreement with Viatris for Sotagliflozin

  • Announced an exclusive licensing agreement with Viatris for rights to sotagliflozin in all global markets outside of the U.S. and Europe.
  • Received an upfront payment of $25 million, and eligible to receive $197 million in additional potential regulatory and sales milestones and tiered royalties ranging from low-double-digit to upper-teens percentages of annual net sales.

ZYNQUISTA (sotagliflozin) for Type 1 Diabetes

  • Following the discussion and feedback from the recent Advisory Committee meeting held for ZYNQUISTA, the company continues to work toward the Prescription Drug User Fee Act (PDUFA) target action date of December 20, 2024.
  • The Advisory Committee voted 11 to 3 that the benefits of ZYNQUISTA do not outweigh the risks in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD), as defined in the voting question as having estimated glomerular filtration rate (eGFR) >45 to <60 mL/min.1.73 m2 or eGFR >60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g. As part of the discussion, certain committee members expressed support for sotagliflozin in alternative sub-populations of people with T1D and CKD, where they believed the benefits potentially outweigh the risks. The advisory committee meeting also included substantial patient and medical community support for the approval of ZYNQUISTA and the potential for the first new adjunct to insulin in over 100 years.

INPEFA (sotagliflozin) for Heart Failure

  • Continued to make progress on the INPEFA launch, with third-quarter net sales of $1.7 million and market access discussions ongoing. Experienced growth in demand with an increase of 18 percent in active INPEFA prescribers.
  • Completed strategic repositioning and reprioritization of SG&A investment, including a reduction in field force by approximately 50 percent to focus on a targeted set of prescribers.

Sotagliflozin for HCM

  • Enrollment is underway in SONATA HCM, a pivotal Phase 3 placebo-controlled study with a targeted enrollment of 500 patients with obstructive or nonobstructive hypertrophic cardiomyopathy (HCM).

LX9211 for DPNP

  • LX9211 is an orally-delivered, small molecule drug candidate for the treatment for DPNP. LX9211 has the potential to become the first non-opioid drug therapy approved in neuropathic pain in more than 20 years. 
  • Completed patient screening ahead of schedule in the PROGRESS Phase 2b dose optimization study of LX9211 in DPNP. Topline data from the PROGRESS study is now anticipated in Q1 2025.

LX9851 for Obesity and Associated Cardiometabolic Disorders

  • Data from recent Obesity Week 2024 presentations summarize the preclinical efficacy and mechanism of action of LX9851. 
  • Lexicon’s ACSL5-inhibitor LX9851, a novel, non-incretin oral development candidate, is progressing in IND-enabling studies and is on track for a mid 2025 IND submission.

Third Quarter 2024 Financial Highlights

Revenues: Revenues for the third quarter of 2024 increased to $1.8 million from $0.2 million for the corresponding period from 2023 reflecting increased product revenues from sales of INPEFA.

Research and Development (R&D) Expenses: Research and development expenses for the third quarter of 2024 increased to $25.8 million from $17.6 million for the corresponding period in 2023 primarily due to investments in Phase 2 and 3 clinical trials, including the SONATA Phase 3 study of sotagliflozin in HCM and the PROGRESS Phase 2b study of LX9211 in DPNP.

Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the third quarter of 2024 increased to $39.6 million from $32.2 million for the corresponding period in 2023. The increase in 2024 reflects higher marketing costs in conjunction with the commercialization of INPEFA and the severance costs resulting from the partial reduction in the field force in September 2024.

Net Loss: Net loss for the third quarter of 2024 was $64.8 million, or $0.18 per share, as compared to a net loss of $50.5 million, or $0.21 per share, in the corresponding period in 2023. For the third quarters of 2024 and 2023, net loss included non-cash, stock-based compensation expense of $2.8 million and $3.9 million, respectively.

Cash and Investments: As of September 30, 2024, Lexicon had $258.4 million in cash and investments, as compared to $170.0 million as of December 31, 2023. The $25 million upfront payment under the exclusive licensing agreement with Viatris for sotagliflozin outside of the US and Europe was received in the fourth quarter of 2024.

Conference Call and Webcast Information
Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update.  The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 1004487. The live webcast and replay may be accessed by visiting Lexicon’s website at  www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 
Lexicon Pharmaceuticals, Inc.
Selected Financial Data
         
Consolidated Statements of Operations Data Three Months Ended September 30, Nine Months Ended September 30,
(In thousands, except per share data) 2024 2023 2024 2023
  (Unaudited) (Unaudited)
Revenues:        
Net product revenue $1,741  $148  $4,451  $438 
Royalties and other revenue  9   14   76   64 
Total revenues  1,750   162   4,527   502 
Operating expenses:        
Cost of sales  71   7   268   15 
Research and development, including stock-based        
compensation of $1,460, $1,337, $4,733, and $3,842, respectively  25,780   17,558   57,795   44,125 
Selling, general and administrative, including stock-based        
compensation of $1,341, $2,561, $7,229, and $7,286, respectively  39,592   32,228   110,844   81,375 
Total operating expenses  65,443   49,793   168,907   125,515 
Loss from operations  (63,693)  (49,631)  (164,380)  (125,013)
Interest and other expense  (4,562)  (3,899)  (11,721)  (7,680)
Interest income and other, net  3,444   3,005   9,464   5,330 
Net loss $(64,811) $(50,525) $(166,637) $(127,363)
         
Net loss per common share, basic and diluted $(0.18) $(0.21) $(0.54) $(0.60)
         
Weighted average common shares outstanding,        
basic and diluted  361,492   244,925   306,109   213,112 
         
         
         
  As of As of    
Consolidated Balance Sheet Data September 30, 2024 December 31, 2023    
(In thousands)        
Cash and investments $258,369  $170,026     
Property and equipment, net  2,135   1,987     
Goodwill  44,543   44,543     
Total assets  321,123   229,429     
Long-term debt, net  99,895   99,508     
Accumulated deficit  (1,933,476)  (1,766,839)    
Total stockholders' equity  178,512   93,110     
         

For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

About INPEFA® (sotagliflozin)
Discovered using Lexicon’s unique approach to gene science, INPEFA® (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.

INDICATION

INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

  • heart failure or
  • type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors

IMPORTANT SAFETY INFORMATION

Dosing: Assess renal function and volume status and, if necessary, correct volume depletion prior to initiation of INPEFA. INPEFA dosing for patients with decompensated heart failure may begin when patients are hemodynamically stable, including when hospitalized or immediately upon discharge.

Contraindications: INPEFA is contraindicated in patients with hypersensitivity to INPEFA or any of its components.

Ketoacidosis: INPEFA increases the risk of ketoacidosis in patients with type 1 diabetes mellitus (T1DM). Type 2 diabetes Mellitus (T2DM) and pancreatic disorders are also risk factors. The risk of ketoacidosis may be greater with higher doses. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes using sodium glucose transporter 2 (SGLT2) inhibitors. Before initiating INPEFA, assess risk factors for ketoacidosis. Consider ketone monitoring in patients with T1DM and consider ketone monitoring in others at risk for ketoacidosis and educate patients on the signs/symptoms of ketoacidosis. Patients receiving INPEFA may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis. INPEFA is not indicated for glycemic control. Assess patients who present with signs and symptoms of metabolic acidosis or ketoacidosis, regardless of blood glucose level. If suspected, discontinue INPEFA, evaluate, and treat promptly. Monitor patients for resolution of ketoacidosis before restarting INPEFA.

Volume Depletion: INPEFA can cause intravascular volume depletion which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. There have been post-marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors. Patients with impaired renal function (eGFR < 60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before initiating INPEFA in patients with one or more of these characteristics, assess volume status and renal function, and monitor for signs and symptoms of hypotension during therapy.

Urosepsis and Pyelonephritis: Treatment with SGLT2 inhibitors, including INPEFA, increases the risk for urinary tract infections. Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been reported. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly.

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Insulin and insulin secretagogues are known to cause hypoglycemia. INPEFA may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used with INPEFA.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Reports of Fournier’s Gangrene, a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in post-marketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors. Assess patients who present with pain, tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue INPEFA, closely monitor patient signs and symptoms, and provide appropriate alternative therapy for heart failure.

Genital Mycotic Infections: INPEFA increases the risk of genital mycotic infections. Monitor and treat as appropriate.

Urinary Glucose Test and 1,5-anhydroglucitol (1,5-AG) Assay: these are not reliable for patients taking SGLT2 inhibitors. Use alternative testing methods to monitor glucose levels.

Common Adverse Reactions: the most commonly reported adverse reactions (incidence ≥ 5%) were urinary tract infection, volume depletion, diarrhea, and hypoglycemia.

Drug Interactions:

  • Digoxin: Monitor patients appropriately as there is an increase in the exposure of digoxin when coadministered with INPEFA 400 mg.
  • Uridine 5'-diphospho-glucuronosyltransferase (UGT) Inducer: The coadministration of rifampicin, an inducer of UGTs, with sotagliflozin resulted in a decrease in the exposure of sotagliflozin.
  • Lithium: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently during INPEFA initiation and with dosage changes.

Use in Specific Populations:

  • Pregnancy and Lactation: INPEFA is not recommended during the second and third trimesters of pregnancy, nor while breastfeeding.
  • Geriatric Use: No INPEFA dosage change is recommended based on age. No overall differences in efficacy were detected between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Elderly patients may be at increased risk for volume depletion adverse reactions, including hypotension.
  • Renal Impairment: INPEFA was evaluated in patients with chronic kidney disease (eGFR 25 to 60 mL/min/1.73 m2) and in patients with heart failure with eGFR < 60 mL/min/1.73 m2. The safety profile of INPEFA across eGFR subgroups in these studies was consistent with the known safety profile. There was an increase in volume-related adverse events (e.g., hypotension, dizziness) in patients with eGFR < 30 mL/min/1.73m2 relative to the overall safety population. Efficacy and safety studies with INPEFA did not enroll patients with an eGFR less than 25 mL/min/1.73 m2 or on dialysis. After starting therapy in the studies, patients were discontinued if eGFR fell below 15 mL/min/1.73 m2 or were initiated on chronic dialysis.
  • Hepatic Impairment: INPEFA is not recommended in patients with moderate or severe hepatic impairment.

Click here for full Prescribing Information.
https://www.lexpharma.com/inpefa-US-PI.pdf


FAQ

What were Lexicon Pharmaceuticals (LXRX) Q3 2024 INPEFA sales?

Lexicon Pharmaceuticals reported INPEFA net sales of $1.7 million in Q3 2024.

What was LXRX's net loss per share in Q3 2024?

Lexicon Pharmaceuticals reported a net loss of $0.18 per share in Q3 2024.

When is the PDUFA date for LXRX's ZYNQUISTA?

The PDUFA target action date for ZYNQUISTA is December 20, 2024.

What was the outcome of LXRX's FDA Advisory Committee meeting for ZYNQUISTA?

The Advisory Committee voted 11 to 3 that the benefits of ZYNQUISTA do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

LXRX Rankings

LXRX Latest News

LXRX Stock Data

311.05M
346.22M
1.15%
82.02%
7.93%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
THE WOODLANDS